Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.34 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.34 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 5/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethanolamine SCHEMBL30336235 | 0.96 | — | — | |
| SCHEMBL10892467 | 0.96 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNATDP1TP53ALOX15 | |
| SCHEMBL2748224 | 0.96 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNATDP1TP53ALOX15 | |
| Diethanolamine SCHEMBL1835599 | 0.96 | — | — | |
| SCHEMBL64351 | 0.96 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNATDP1TP53ALOX15 | |
| SCHEMBL16041149 | 0.96 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNATDP1TP53ALOX15 | |
| Hydrochloric Acid SCHEMBL650652 | 0.92 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNATDP1TP53ALOX15 | |
| Diethanolamine SCHEMBL23363665 | 0.91 | TSHR (0.36) | SMN1; SMN2LMNATDP1TP53ALOX15 | |
| Diethanolamine SCHEMBL5307430 | 0.91 | TSHR (0.36) | SMN1; SMN2LMNATDP1TP53ALOX15 | |
| Diethanolamine SCHEMBL5843119 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107801395-B | Process for preparing amphiphilic imidazolinium compounds | 拜耳动物保健有限责任公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-3292106-B1 | PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | BAYER ANIMAL HEALTH GMBH (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-10479768-B2 | Process for the preparation of amphiphilic imidazolinium compounds | BAYER ANIMAL HEALTH GMBH (DE) | 2019-11-19 | — | — | US | disclosed |
| US-20180148415-A1 | IMPROVED PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2018-05-31 | — | — | US | disclosed |
| EP-3292106-A1 | PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | Bayer Animal Health GmbH (DE) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016177693-A1 | PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479768-B2 | Process for the preparation of amphiphilic imidazolinium compounds | IPO8, IPO9, IPO7 | CHRM2 3370/4885SLC6A2 2294/4885ADRA1A 2568/4885 |
| US-20180148415-A1 | IMPROVED PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | IPO8, IPO9, IPO7 | CHRM2 3767/4885SLC6A2 1998/4885ADRA1A 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.